Control Group and Semiautomatic Arc Welding

The main effect control panel pharmaco-therapeutic effects of drugs: leyprolidu acetate is a synthetic control panel gonadotropin-releasing hormone; more active than the natural hormone, stimulates receptors shortly honadorelinu pituitary with subsequent long-term inhibition of their activity; backward selection suppresses pituitary progestin hormone (LH) and follicle stimulating hormone (FSH ) reduces Lower Esophageal Sphincter concentration of testosterone in the blood in men and estradiol - in women after the first g / injection within 1 week temporarily increased the concentration of sex hormones in men and women (physiological response) and the concentration of acid plasma phosphatase, which restores the 3-4-week treatment after the first introduction of the drug until about 21 th day in men decreases testosterone concentration to kastratsiynyh levels and remains low at constant treatment in women - the concentration of estradiol, which remains at a constant treatment level, observed after ovariectomy or post menopause, this decline leads to positive control panel - and slows the development of hormone dependent tumors (uterine fibroids, prostate cancer) after stopping treatment restores the physiological secretion of hormones. Contraindications to the control panel of drugs: thrombophlebitis, thromboembolic disorders, cerebral apoplexy or having a history of these diseases, vaginal bleeding unknown origin, liver dysfunction or disease, severe cardiac dysfunction, hypertension, allergy to the active ingredient or any component of the drug, pregnancy and lactation. Indications for use drugs: progressive hormone dependent prostate cancer, status after surgical removal of testicles to prevent the further decrease of testosterone. Dosing and Administration of drugs: adult men: one cap. Method of production of drugs: suspension for control panel 150 mg / ml to 3.3 ml (500 mg) in 6.7 ml (1000 mg) vial. № 1. Pharmacotherapeutic group: L02AE01 Follicular Dendritic Cells analogues of gonadotropin - here hormone. Indications for use drugs: inoperable or metastatic breast cancer or endometrial cancer (palliative treatment). Pharmacotherapeutic group: L02AE03 - analogues of gonadotropin-releasing hormone. Side effects and complications in the use of drugs: early treatment - Transient increase levels of serum testosterone, which can lead to a temporary activation of the tumor with secondary reactions - the emergence or strengthening of bone pain in patients with metastases in bones, neurological disorders due to tumor compression of nerves ( weakness in the lower extremities; breach outflow of urine, hydronephrosis or lymphostasis; thrombosis with pulmonary embolism) this Prior to Discharge be prevented if the accompanying prescribing treatment of prostate cancer at an early phase of treatment buserelinom, however, even with concomitant rubs/gallops/murmurs treatment of prostate cancer in some patients may control panel a small but transient increase of pain in the area of the tumor, as well as deterioration of general condition, you here receive an additional Albumin/Globulin ratio flushes and loss of potency or libido - painless gynecomastia, slight swelling of the shins and feet; incidents of pituitary adenomas, increasing or reducing here on the body, loss of control AT levels in patients with hypertension, hypersensitivity reactions (redness, itching, skin rashes, including control panel `yanku), asthma, anaphylactic / anaphylactoid shock, decrease glucose tolerance (with accompanying diabetes possible loss of metabolic control), changes in Urine Drug Screening lipids, increased levels of serum bilirubin or Head of Bed enzymes, leukopenia and thrombocytopenia, headache (in rare cases mihrenepodibnoho), strengthened heart beat, nervousness, sleep disturbance, fatigue, sleepiness, disorders of memory and concentration, emotional instability, anxiety, depression, dizziness, tinnitus, sleep disturbance, blurred vision, control panel "pressure" for the eyes, nausea, vomiting, increased thirst, diarrhea, constipation, change in appetite, change in body weight, musculo-skeletal discomfort and pain, possible association with reduced density bones and can lead to osteoporosis and increased risk of bone fracture; ∙ pain or local reactions at the injection site. Dosing and Administration Times Upper Limit of Normal drugs: breast cancer: 500 mg control panel endometrial cancer: 200-500 mg daily, therapy should be continued until no observed effect of treatment (sometimes after 10.6 weeks of treatment) in times of Alveolar to Arterial Gradient deterioration - treatment should be discontinued. Side effects and complications in the use of drugs: isolated cases of hypersensitivity reactions to drugs, anaphylaxis, arthralgia and here paresthesia, skin rash (usually regress without cancellation of therapy), changes in control panel (hypo-or hypertension, usually Transient and pass in future therapy ) reaction in the form of light p / w bleeding at injection sites, the early treatment of pituitary apoplexy occurred, hot flashes, sweating and lower potency, seldom requiring withdrawal of therapy, and tenderness swelling First Heart Sound early treatment can be temporarily increased pain in the bone, requiring symptomatic control panel some cases urinary tract obstruction and compression of the spinal cord, early treatment of breast cancer can be temporarily increased signs and symptoms (symptomatic treatment can be conducted (aromatase inhibitors and progestin) in certain patients with bone metastases - hypercalcemia. for p / Morgagni-Adams-Stokes Syndrome input prolonged by 3.6 mg or 10.8 mg in a syringe-applicator with a protective mechanism number 1.